Cubic Sensor And Instrument Co.,Ltd (688665.SH) shareholders plan to reduce their holdings by no more than 3% in total.
Cubic Sensor and Instrument Co., Ltd. (688665.SH) announced that it recently received a "Letter of Intent to Reduce Shareholdings" from its shareholders. Due to the shareholders' own funding needs, Zhigan Technology, a shareholder holding more than 5% of the company, and employee shareholding platforms Wuhan Juyou and Wuhan Gaisen intend to reduce their holdings of the company's shares through centralized bidding and block trades. Among them, Zhigan Technology plans to reduce its holdings by no more than 1,542,600 shares, accounting for no more than 1.5245% of the company's total share capital; Wuhan Juyou plans to reduce its holdings by no more than 1,070,700 shares, accounting for no more than 1.0581% of the company's total share capital; Wuhan Gaisen plans to reduce its holdings by no more than 422,400 shares, accounting for no more than 0.4174% of the company's total share capital.
Cubic Sensor And Instrument Co.,Ltd (688665.SH) announced that the company recently received a "Letter of Intent Regarding Share Reduction by Shareholders" from its shareholders. Due to the shareholders' own funding needs, Zhigan Technology, a shareholder holding more than 5% of the company's shares, and the employee shareholding platforms Wuhan Juyou and Wuhan Gaisen plan to reduce their holdings of the company's shares through centralized bidding and block trades. Among them, Zhigan Technology plans to reduce its holdings by no more than 1,542,600 shares, accounting for no more than 1.5245% of the company's total share capital; Wuhan Juyou plans to reduce its holdings by no more than 1,070,700 shares, accounting for no more than 1.0581% of the company's total share capital; Wuhan Gaisen plans to reduce its holdings by no more than 422,400 shares, accounting for no more than 0.4174% of the company's total share capital.
Related Articles
General Manager Cheng Zhenghui of APT Medical Inc. (688617.SH) plans to reduce his shareholding by no more than 1.5%.
EFORT Intelligent Equipment (688165.SH) shareholder Xinwei Jishi and its concerted parties plan to reduce their shareholding by no more than 3%.
Shanghai Shen Lian Biomedical Corporation (688098.SH): Phase II clinical trial of UB-221 for the treatment of chronic spontaneous urticaria meets primary endpoint
General Manager Cheng Zhenghui of APT Medical Inc. (688617.SH) plans to reduce his shareholding by no more than 1.5%.
EFORT Intelligent Equipment (688165.SH) shareholder Xinwei Jishi and its concerted parties plan to reduce their shareholding by no more than 3%.
Shanghai Shen Lian Biomedical Corporation (688098.SH): Phase II clinical trial of UB-221 for the treatment of chronic spontaneous urticaria meets primary endpoint
RECOMMEND
